Matches in Wikidata for { <http://www.wikidata.org/entity/Q66066337> ?p ?o ?g. }
Showing items 1 to 35 of
35
with 100 items per page.
- Q66066337 description "clinical trial" @default.
- Q66066337 description "ensayu clínicu" @default.
- Q66066337 description "klinisch onderzoek" @default.
- Q66066337 description "клінічне випробування" @default.
- Q66066337 name "A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)" @default.
- Q66066337 name "A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)" @default.
- Q66066337 type Item @default.
- Q66066337 label "A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)" @default.
- Q66066337 label "A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)" @default.
- Q66066337 prefLabel "A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)" @default.
- Q66066337 prefLabel "A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)" @default.
- Q66066337 P1132 Q66066337-70BC3926-4968-43CA-8E9F-F7F2EEB5C410 @default.
- Q66066337 P1476 Q66066337-DF9936B3-FABE-4947-A9BA-CE5981E8C91E @default.
- Q66066337 P2899 Q66066337-BEF693B8-47A6-4D84-9685-B056AA42BE43 @default.
- Q66066337 P3098 Q66066337-68A70736-4FF3-4E14-B848-3190BCCA7986 @default.
- Q66066337 P31 Q66066337-A90E67DB-E631-41A5-B003-B979D954AA49 @default.
- Q66066337 P4844 Q66066337-3319E195-F104-4D45-9843-0DEE9CC28534 @default.
- Q66066337 P4844 Q66066337-90F26E75-ED02-4445-9DAF-773474F36CD6 @default.
- Q66066337 P4844 Q66066337-B74BA2CB-F8CA-4D17-8BB5-59B5F9DA1E70 @default.
- Q66066337 P580 Q66066337-12109960-9CB6-4351-80A8-2036447E7CD9 @default.
- Q66066337 P582 Q66066337-E044C864-558A-4089-8C87-81E2C243C2F2 @default.
- Q66066337 P6099 Q66066337-670F198B-877F-427A-99FD-2EFEE87D3C52 @default.
- Q66066337 P8363 Q66066337-2E7911A4-46AF-4877-89A5-361E53634E44 @default.
- Q66066337 P1132 "+735" @default.
- Q66066337 P1476 "A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)" @default.
- Q66066337 P2899 "+18" @default.
- Q66066337 P3098 "NCT03976362" @default.
- Q66066337 P31 Q30612 @default.
- Q66066337 P4844 Q13896859 @default.
- Q66066337 P4844 Q415588 @default.
- Q66066337 P4844 Q423762 @default.
- Q66066337 P580 "2019-07-02T00:00:00Z" @default.
- Q66066337 P582 "2024-05-06T00:00:00Z" @default.
- Q66066337 P6099 Q42824827 @default.
- Q66066337 P8363 Q78089383 @default.